Full-Time

Senior Manager

Government Affairs & Public Policy

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

No salary listed

Senior, Expert

Munich, Germany

Hybrid

Hybrid-Eligible role allows for remote work up to two days per week.

Category
Public Health
Biology & Biotech
Required Skills
Public Policy
Requirements
  • Experience in Government Affairs & Public Policy in pharma/biopharma on either the agency or corporate side or within government or administration
  • Relevant Education
  • A high level of energy and passion towards patients, science and healthcare systems
  • A desire to work in the corporate culture of a highly innovative company aimed at redefining health, and transforming lives with new medicines
  • Display solid ethics and fully comply with all regulatory, legal and industry codes of conduct for governmental affairs activities
  • Ability and willingness to travel
  • Fluency in English and German written and spoken
Responsibilities
  • Support developing Government Affairs and Public Policy activities for Vertex
  • Represent and lead Vertex engagement in selected industry organizations and with key stakeholders
  • Proactively monitor and analyse relevant pharmaceutical, healthcare and regulatory policy
  • Exemplifying Vertex’s core values in fulfilling these job duties
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approval for expanded cystic fibrosis treatment could boost European market penetration.
  • Stevens Capital's $829,000 investment shows strong investor confidence in Vertex.
  • Paul Negulescu's award enhances Vertex's reputation in cystic fibrosis research.

What critics are saying

  • Recent layoffs and asset axing suggest potential financial strain or strategic shifts.
  • $400 million impairment charge indicates challenges in diabetes treatment pipeline.
  • Uncertain market prospects for diabetes cell therapy could affect investor confidence.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative cell therapies involve modifying cells outside the body.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

BioSpace
Jun 23rd, 2025
Vertex's Cell Therapy Could Be 'Functional Cure' for Diabetes, but Market Prospects Uncertain

Friday's readout at ADA 2025 comes after Vertex axed its cell therapy - device combo VX-264, also being developed for T1D, and swallowed a $400 million impairment charge as a result.

Pharmalive
Jun 11th, 2025
After axing diabetes asset, Vertex lays off 140 staff

After axing diabetes asset, Vertex lays off 140 staff.

PBN
Jun 10th, 2025
Vertex Pharmaceuticals to lay off 125 R.I. employees

PROVIDENCE - Vertex Pharmaceuticals Inc. is laying off 125 people in Rhode Island, according to a WARN notice filed with the R.I. Department of Labor and Training on June 8.

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.